|
1
|
Heusch G: Myocardial ischemia/reperfusion:
Translational pathophysiology of ischemic heart disease. Med.
5:10–31. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sánchez-Hernández CD, Torres-Alarcón LA,
González-Cortés A and Peón AN: Ischemia/reperfusion injury:
Pathophysiology, current clinical management, and potential
preventive approaches. Med Inflamm. 2020:84053702020. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zhang S, Yan F, Luan F, Chai Y, Li N, Wang
YW, Chen ZL, Xu DQ and Tang YP: The pathological mechanisms and
potential therapeutic drugs for myocardial ischemia reperfusion
injury. Phytomedicine. 129:1556492024. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Toldo S and Abbate A: The role of the
NLRP3 inflammasome and pyroptosis in cardiovascular diseases. Nat
Rev Cardiol. 21:219–237. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Vasudevan SO, Behl B and Rathinam VA:
Pyroptosis-induced inflammation and tissue damage. Semin Immunol.
69:1017812023. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
He J, Liu D, Zhao L, Zhou D, Rong J, Zhang
L and Xia Z: Myocardial ischemia/reperfusion injury: Mechanisms of
injury and implications for management (review). Exp Ther Med.
23:4302022. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Jiang Z, Cui X, Qu P, Shang C, Xiang M and
Wang J: Roles and mechanisms of puerarin on cardiovascular disease:
A review. Biomed Pharmacother. 147:1126552022. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Gao M, Zhang Z, Lai K, Deng Y, Zhao C, Lu
Z and Geng Q: Puerarin: A protective drug against
ischemia-reperfusion injury. Front Pharmacol. 13:9276112022.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lyu Q, Xue W, Liu R, Ma Q, Kasaragod VB,
Sun S, Li Q, Chen Y, Yuan M, Yang Y, et al: A brain-to-gut signal
controls intestinal fat absorption. Nature. 634:936–943. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wang K, Sun Y, Zhu K, Liu Y, Zheng X, Yang
Z, Man F, Huang L, Zhu Z, Huang Q, et al: Anti-pyroptosis
biomimetic nanoplatform loading puerarin for myocardial infarction
repair: From drug discovery to drug delivery. Biomaterials.
314:1228902025. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Sun S, Gong D, Liu R, Wang R, Chen D, Yuan
T, Wang S, Xing C, Lv Y, Du G and Fang L: Puerarin Inhibits
NLRP3-Caspase-1-GSDMD-Mediated Pyroptosis via P2X7 receptor in
cardiomyocytes and macrophages. Int J Mol Sci. 24:131692023.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhang Q, Liu J, Duan H, Li R, Peng W and
Wu C: Activation of Nrf2/HO-1 signaling: An important molecular
mechanism of herbal medicine in the treatment of atherosclerosis
via the protection of vascular endothelial cells from oxidative
stress. J Adv Res. 34:43–63. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Qiu Z, He Y, Ming H, Lei S, Leng Y and Xia
ZY: Lipopolysaccharide (LPS) aggravates high Glucose- and
Hypoxia/reoxygenation-induced injury through activating
ROS-Dependent NLRP3 Inflammasome-mediated pyroptosis in H9C2
cardiomyocytes. J Diabetes Res. 2019:81518362019. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhang J, Pan W, Zhang Y, Tan M, Yin Y, Li
Y, Zhang L, Han L, Bai J, Jiang T and Li H: Comprehensive overview
of Nrf2-related epigenetic regulations involved in
ischemia-reperfusion injury. Theranostics. 12:6626–6645. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Jiang S, Qiu S, Mu Y, Liu C, Han Y, Jiang
J and Wang Y: Puerarin reduces susceptibility to ventricular
arrhythmias and inhibits ferroptosis via Sirt1/Nrf2 signaling in
high-fat-diet rats. Free Radic Biol Med. 227:472–484. 2025.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
MacArthur Clark JA and Sun D: Guidelines
for the ethical review of laboratory animal welfare People's
Republic of China National Standard GB/T 35892-2018 [Issued 6
February 2018 Effective from 1 September 2018]. Animal Model Exp
Med. 3:103–113. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chen L, Mao LS, Xue JY, Jian YH, Deng ZW,
Mazhar M, Zou Y, Liu P, Chen MT, Luo G and Liu MN: Myocardial
ischemia-reperfusion injury: The balance mechanism between
mitophagy and NLRP3 inflammasome. Life Sci. 355:1229982024.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhang AY, Su JB, Sun HT, Liu Q, Li R,
Zhang Y, Wang Y, Wang MY, Ji LM, Gao SQ, et al: Stachyose
ameliorates myocardial ischemia-reperfusion injury by inhibiting
cardiomyocyte ferroptosis and macrophage pyroptosis. Int
Immunopharmacol. 143:1133342024. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Luo T, Jia X, Feng WD, Wang JY, Xie F,
Kong LD, Wang XJ, Lian R, Liu X, Chu YJ, et al: Bergapten inhibits
NLRP3 inflammasome activation and pyroptosis via promoting
mitophagy. Acta Pharmacol Sin. 44:1867–1878. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Pagliaro P and Penna C: Inhibitors of
NLRP3 inflammasome in ischemic heart disease: Focus on functional
and redox aspects. Antioxidants (Basel). 12:13962023. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Coll RC, Schroder K and Pelegrín P: NLRP3
and pyroptosis blockers for treating inflammatory diseases. Trends
Pharmacol Sci. 43:653–668. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Broz P and Dixit VM: Inflammasomes:
Mechanism of assembly, regulation and signalling. Nat Rev Immunol.
16:407–420. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhang L, Jiang YH, Fan C, Zhang Q, Jiang
YH, Li Y and Xue YT: MCC950 attenuates doxorubicin-induced
myocardial injury in vivo and in vitro by inhibiting NLRP3-mediated
pyroptosis. Biomed Pharmacother. 143:1121332021. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Liao Y, Liu K and Zhu L: Emerging roles of
inflammasomes in cardiovascular diseases. Front Immunol.
13:8342892022. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kawaguchi M, Takahashi M, Hata T, Kashima
Y, Usui F, Morimoto H, Izawa A, Takahashi Y, Masumoto J, Koyama J,
et al: Inflammasome activation of cardiac fibroblasts is essential
for myocardial ischemia/reperfusion injury. Circulation.
123:594–604. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhou S, Li Y, Hong Y, Zhong Z and Zhao M:
Puerarin protects against sepsis-associated encephalopathy by
inhibiting NLRP3/caspase-1/GSDMD pyroptosis pathway and reducing
blood-brain barrier damage. Eur J Pharmacol. 945:1756162023.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wang K, Tang Z, Liu S, Liu Y, Zhang H and
Zhan H: Puerarin protects renal ischemia-reperfusion injury in rats
through NLRP3/Caspase-1/GSDMD pathway. Acta Cir Bras.
38:e3873232023. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wang L, Xie X, Chen Q, Chen Y, Xu X and
Liang T: Puerarin reduces diabetic nephropathy-induced podocyte
pyroptosis by modulating the SIRT1/NLRP3/caspase-1 pathway. Mol
Cell Endocrinol. 595:1124092025. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Peng ZT and Liu H: Puerarin attenuates
LPS-induced inflammatory injury in gastric epithelial cells by
repressing NLRP3 inflammasome-mediated apoptosis. Toxicol In Vitro.
81:1053502022. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Chang X, Liu J, Wang Y, Guan X and Liu R:
Mitochondrial disorder and treatment of ischemic cardiomyopathy:
Potential and advantages of Chinese herbal medicine. Biomed
Pharmacother. 159:1141712023. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Peng JF, Salami OM, Lei C, Ni D, Habimana
O and Yi GH: Targeted mitochondrial drugs for treatment of
myocardial ischaemia-reperfusion injury. J Drug Target. 30:833–844.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Niu P, Sun Y, Wang S, Li G, Tang X and Sun
J, Pan C and Sun J: Puerarin alleviates the ototoxicity of
gentamicin by inhibiting the mitochondria-dependent apoptosis
pathway. Mol Med Rep. 24:8512021. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Sheng G, Wu Y, Yao L, Liu H, Zhang P, Song
C, Wu G and Zhu H: Puerarin improves the comorbidity of chronic
pain and depression by binding with Bax and reducing mitochondrial
dysfunction. Mol Pain. 21:174480692513352302025. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Dhalla NS, Shah AK, Adameova A and
Bartekova M: Role of oxidative stress in cardiac dysfunction and
subcellular defects due to ischemia-reperfusion injury.
Biomedicines. 10:14732022. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Xiang M, Lu Y, Xin L, Gao J, Shang C,
Jiang Z, Lin H, Fang X, Qu Y and Wang Y: Role of oxidative stress
in reperfusion following myocardial ischemia and its treatments.
Oxid Med Cell Longev. 2021:66140092021. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Geng J and Zhang C: Liensinine attenuates
inflammatory response and oxidative stress by activation of
Nrf2/HO-1 signaling in L-NAME-induced gestational hypertension.
Naunyn Schmiedebergs Arch Pharmacol. 398:14089–14098. 2025.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
El-Emam SZ, Soubh AA, Al-Mokaddem AK and
Abo El-Ella DM: Geraniol activates Nrf-2/HO-1 signaling pathway
mediating protection against oxidative stress-induced apoptosis in
hepatic ischemia-reperfusion injury. Naunyn Schmiedebergs Arch
Pharmacol. 393:1849–1858. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Yang X, Liu Y, Cao J, Wu C, Tang L, Bian
W, Chen Y, Yu L, Wu Y, Li S, et al: Targeting epigenetic and
post-translational modifications of NRF2: Key regulatory factors in
disease treatment. Cell Death Discov. 11:1892025. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Kuo PC, Weng WT, Scofield BA, Paraiso HC,
Yu II and Yen JJ: Ischemia-induced endogenous Nrf2/HO-1 axis
activation modulates microglial polarization and restrains ischemic
brain injury. Front Immunol. 15:14405922024. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Manavi MA, Mohammad Jafari R, Shafaroodi H
and Dehpour AR: The Keap1/Nrf2/ARE/HO-1 axis in epilepsy: Crosstalk
between oxidative stress and neuroinflammation. Int
Immunopharmacol. 153:1143042025. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Sun YY, Zhu HJ, Zhao RY, Zhou SY, Wang MQ,
Yang Y and Guo ZN: Remote ischemic conditioning attenuates
oxidative stress and inflammation via the Nrf2/HO-1 pathway in MCAO
mice. Redox Biol. 66:1028522023. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Shi Y, Yang Y, Xu W, Shi D, Xu W, Fu X, Lv
Q, Xia J and Shi F: E3 ubiquitin ligase SYVN1 is a key positive
regulator for GSDMD-mediated pyroptosis. Cell Death Dis.
13:1062022. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Huang Y, Wu H, Hu Y, Zhou C, Wu J, Wu Y,
Wang H, Lenahan C, Huang L, Nie S, et al: Puerarin attenuates
oxidative stress and ferroptosis via AMPK/PGC1α/Nrf2 pathway after
subarachnoid hemorrhage in rats. Antioxidants (Basel). 11:12592022.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Hou BY, Zhao YR, Ma P, Xu CY, He P, Yang
XY, Zhang L, Qiang GF and DU GH: Hypoglycemic activity of puerarin
through modulation of oxidative stress and mitochondrial function
via AMPK. Chin J Nat Med. 18:818–826. 2020.PubMed/NCBI
|
|
45
|
Jeon YD, Lee JH, Lee YM and Kim DK:
Puerarin inhibits inflammation and oxidative stress in dextran
sulfate sodium-induced colitis mice model. Biomed Pharmacother.
124:1098472020. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Yang M, Xia L, Song J, Hu H, Zang N, Yang
J, Zou Y, Wang L, Zheng X, He Q, et al: Puerarin ameliorates
metabolic dysfunction-associated fatty liver disease by inhibiting
ferroptosis and inflammation. Lipids Health Dis. 22:2022023.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Wang J, Zheng Q, Chen Z, Liu X, Wan S and
Wang L: Puerarin alleviates renal ischemia/reperfusion injury by
inhibiting apoptosis and endoplasmic reticulum stress via Nrf2/HO-1
pathway. Iran J Basic Med Sci. 28:187–193. 2025.PubMed/NCBI
|
|
48
|
Chen ZQ, Zhou Y, Huang JW, Chen F, Zheng
J, Li HL, Li T and Li L: Puerarin pretreatment attenuates
cardiomyocyte apoptosis induced by coronary microembolization in
rats by activating the PI3K/Akt/GSK-3β signaling pathway. Korean J
Physiol Pharmacol. 25:147–157. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Wang Z, Yu Y, Shao W, Zhao Y, Li Z, Han J,
Wen J, Meng Y, Lin Y and Wang S: Puerarin ameliorates alcoholic
liver disease by regulating intestinal flora and MAPK/Nrf2
signalling pathways. Ecotoxicol Environ Saf. 309:1196992026.
View Article : Google Scholar : PubMed/NCBI
|
